background
debat
articl
plo
medicin
holger
j
nemann
colleagu
describ
new
process
use
world
health
organ
rapidli
develop
clinic
manag
guidelin
emerg
situat
situat
includ
outbreak
emerg
infecti
diseas
author
discuss
develop
rapid
advic
guidelin
pharmacolog
manag
avian
influenza
viru
infect
guidelin
recommend
give
antivir
drug
oseltamivir
dose
mg
twice
daili
five
day
debat
nichola
white
argu
dose
inadequ
robert
webster
elena
govorkova
say
combin
antivir
therapi
use
tim
uyeki
remind
us
clinic
care
patient
entail
much
antivir
treatment
issu
may
also
appli
therapi
patient
hospit
sever
diseas
due
novel
swineorigin
influenza
viru
infect
rapidli
fatal
infect
need
urgent
treatment
optimum
dose
appropri
antimicrobi
dose
ideal
produc
maximum
effect
quickli
possibl
provid
greatest
differenti
live
save
live
lost
toxic
antimicrobi
drug
elimin
rapidli
load
dose
given
provid
therapeut
concentr
soon
possibl
dose
strategi
rapidli
fatal
infect
contrast
dose
recommend
uncompl
infectionssuch
recommend
aim
lower
microorgan
burden
rapid
action
less
import
advers
effect
greater
signific
word
riskbenefit
tradeoff
commonli
term
therapeut
ratio
differ
sever
uncompl
infect
differ
import
implic
treatment
guidelin
accord
world
health
organ
guidelin
formal
advisori
statement
robust
enough
meet
uniqu
circumst
constraint
specif
situat
appli
treatment
guidelin
best
rest
sound
consist
evid
base
randomis
clinic
trial
rct
consid
provid
best
evid
evid
control
trial
insuffici
simpli
nt
guidanc
specif
recommend
still
necessari
inadequ
initi
treatment
lifethreaten
infect
seriou
consequ
therefor
common
sens
argu
recommend
higher
dose
infect
expens
increas
toxic
avoid
possibl
underdos
patient
unusu
pharmacokinet
resist
organ
intraven
administr
possibl
absorpt
gut
intramuscular
inject
site
may
compromis
serious
ill
argu
higher
dose
context
critic
uncertainti
background
concern
liabil
consequ
risk
avers
physician
often
seem
worri
risk
advers
effect
underdos
even
though
antimicrobi
advers
effect
rare
fatal
seldom
infecti
diseas
death
ascrib
administr
inadequ
dose
influenza
regard
mani
greatest
threat
human
health
nation
secur
fortun
human
infect
still
rare
rariti
also
mean
publish
rct
treatment
oral
viral
neuraminidas
inhibitor
oseltamivir
tamiflu
consid
drug
choic
parenter
formul
influenza
replic
rapidli
season
influenza
virus
reach
much
greater
viral
burden
human
influenza
virus
resist
aris
readili
mortal
consist
exce
put
influenza
amongst
lethal
human
infect
experiment
studi
virus
anim
model
suggest
high
dose
long
cours
neuraminidas
inhibitor
provid
optim
treatment
despit
evid
rigor
transpar
process
led
develop
treatment
guidelin
influenza
recommend
adult
dose
mg
twice
daili
five
day
standard
dose
regimen
uncompl
season
influenza
absorb
well
mg
dose
might
provid
maxim
neuraminidas
inhibit
site
infect
patient
serious
ill
influenza
word
might
enough
truth
know
concentrationeffect
relationship
patient
characteris
oseltamivir
dose
mg
given
volunt
high
dose
oseltamivir
reason
well
toler
human
experiment
evid
suggest
could
effect
seem
littl
gain
everyth
lose
use
low
dose
potenti
lifesav
drug
highli
lethal
infect
evidencebas
approach
grade
recommend
assess
develop
evalu
grade
see
http
wwwgradeworkinggrouporg
consid
state
art
guidelin
develop
constrain
lack
rct
evid
higher
dose
oseltamivir
recent
year
hierarchi
qualiti
evid
increasingli
promot
particularli
formul
guidelin
hierarchi
place
randomis
control
trial
rct
summit
variou
form
observ
studi
nestl
foothil
say
rawlin
inform
observ
studi
foothil
inhabit
experiment
investig
analog
similar
condit
process
patholog
pharmacolog
understand
reason
deriv
assess
risk
benefit
also
valuabl
case
pandem
influenza
grade
process
result
dose
recommend
influenza
could
low
contrast
grade
approach
mechanismbas
approach
incorpor
current
understand
lethal
diseas
antimicrobi
pharmacolog
assess
risk
benefit
would
lead
initi
use
highest
oseltamivir
dose
consid
low
risk
major
toxic
influenza
fundament
differ
analyt
deduct
approach
analog
frequentist
versu
bayesian
debat
statist
rawlin
recent
articul
import
limit
reli
much
upon
evid
rct
argu
cogent
greater
use
bayesian
approach
decis
make
recommend
therapeut
intervent
differ
approach
problem
may
yield
differ
result
initi
although
evid
accru
result
two
approach
tend
converg
current
approach
guidelin
develop
may
restrict
littl
direct
evid
rct
current
evidencebas
approach
treatment
guidelin
certainli
need
reconsider
absenc
direct
evid
dose
rapidli
lethal
infect
basic
precept
antimicrobi
pharmacolog
bayesian
prior
common
sens
argu
highest
possibl
dose
antimicrobi
use
least
initi
evid
becom
avail
inform
recommend
natur
sent
messag
scientist
public
health
offici
concern
current
pharmacolog
treatment
human
potenti
pandem
influenza
viru
messag
loud
clear
strategi
reli
singl
antiinfluenza
drug
treatment
wrong
rapid
emerg
season
influenza
virus
resist
oseltamivir
scandinavia
end
littl
antiinfluenza
drug
use
unexpect
resist
virus
contain
neuraminidas
mutat
remark
fit
spread
global
less
year
oseltamivirresist
influenza
virus
still
suscept
neuraminidas
inhibitor
zanamivir
relenza
would
foolish
continu
complac
reli
monotherapi
influenza
virus
segment
rna
genom
errorpron
replic
lack
proofread
mechan
fundament
properti
influenza
virus
guarante
resist
variant
emerg
resist
may
occur
spontan
natur
without
drug
intervent
would
facilit
use
singleag
chemotherapi
oseltamivir
alon
extens
experi
treat
human
immunodefici
viru
hiv
clearli
show
futil
singleag
antivir
therapi
drugresist
hiv
strain
emerg
almost
immedi
patient
receiv
monotherapi
subsequ
success
manag
hiv
multidrug
combin
highli
activ
antiretrovir
therapi
haart
enabl
thousand
patient
control
diseas
live
product
live
haart
target
multipl
function
viru
ie
revers
transcript
protein
synthesi
attach
entri
lesson
hiv
must
appli
influenza
reason
given
continu
antiinfluenza
monotherapi
drug
target
specif
viral
function
avail
partial
truth
simpli
excus
imped
progress
current
two
class
antiinfluenza
drug
avail
adamantan
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
amantadin
resist
predomin
among
season
influenza
virus
ineffect
adamantan
influenza
b
virus
make
use
pointless
fact
use
counterproduct
facilit
select
resist
use
avail
therapi
minim
impact
influenza
outbreak
human
least
ten
clade
influenza
virus
two
domin
clade
affect
human
clade
virus
often
adamantaneresist
repres
clade
adamantanesuscept
clade
suscept
neuraminidas
inhibitor
current
guidelin
suggest
clinician
administ
doubl
dose
oseltamivir
sever
ill
patient
drug
uncertain
absorpt
high
diseas
mortal
howev
given
eas
natur
occur
oseltamivirresist
virus
emerg
becom
domin
neuraminidas
virus
probabl
similar
fate
thu
must
consid
multidrug
approach
manag
patient
combin
chemotherapi
influenza
support
data
anim
model
combin
oseltamivir
amantadin
inhibit
viru
replic
lung
brain
infect
mice
wherea
monotherapi
partial
effect
combin
oseltamivir
ribavirin
polymeras
inhibitor
although
approv
influenza
countri
show
addit
efficaci
clade
though
efficaci
differ
seen
two
differ
strain
combin
oseltamivir
ribavirin
far
optim
mani
approach
combin
therapi
influenza
pipelin
develop
addit
neuraminidas
inhibitor
parenter
drug
formul
new
antivir
target
includ
polymeras
hemagglutinin
molecul
attach
inhibit
modul
overexuber
innat
host
respons
antibodymedi
therapi
combin
antivir
vaccin
strategi
current
develop
neuraminidas
inhibitor
peramivir
three
chemic
group
interact
activesit
residu
neuraminidas
result
tight
bind
slow
rate
dissoci
develop
intraven
intramuscular
drug
formul
also
provid
advantag
system
replic
influenza
virus
longact
singledos
inhal
neuraminidas
inhibitor
probabl
avail
year
potenti
target
drug
develop
includ
surfac
protein
hemagglutinin
polymeras
inhibitor
potent
inhibitor
viral
rna
polymeras
activ
neuraminidas
inhibitorresist
amantadineresist
virus
new
treatment
immunomodulatori
drug
potenti
control
immun
systemmedi
tissu
damag
requir
strong
experiment
evid
adopt
combin
chemotherapi
consist
antiinfluenza
drug
inflamm
inhibitor
eg
celecoxib
mesalazin
recent
report
promis
approach
control
infect
mice
anoth
excit
recent
discoveri
abil
type
ii
diabet
drug
pioglitazon
modul
tissuedamag
compound
innat
immun
respons
without
compromis
cellmedi
viral
clearanc
passiv
administr
human
monoclon
antibodi
hemagglutinin
mice
creation
comprehens
influenza
antibodi
librari
survivor
avian
influenza
also
provid
encourag
data
mani
viru
host
factor
influenc
outcom
diseas
progress
therefor
multipl
antiinfluenza
drug
must
use
effect
treat
prevent
spread
infect
figur
result
experi
suggest
combin
therapi
approach
guard
emerg
resist
strain
thu
propos
combin
adamantan
neuraminidas
inhibitor
immedi
introduc
ribavirin
use
evalu
clinic
trial
proceed
urgenc
emerg
new
respiratori
infect
caus
rapid
sever
outcom
includ
death
present
major
challeng
identifi
optim
clinic
manag
treatment
exampl
earli
sever
acut
respiratori
syndrom
sar
epidem
oral
intraven
ribavirin
administ
patient
sar
assumpt
antivir
medic
would
activ
suspect
respiratori
viral
pathogen
unfortun
unclear
ribavirin
benefici
treatment
patient
sar
hemolyt
anemia
occur
treat
patient
methylprednisolon
also
administ
wide
patient
sar
higher
dose
associ
avascular
necrosi
among
survivor
date
definit
treatment
exist
human
infect
sarsassoci
coronaviru
sarscov
still
challeng
collect
data
control
clinic
treatment
trial
novel
pathogen
sinc
sporad
human
infect
highli
pathogen
avian
influenza
hpai
viru
caus
ill
person
countri
mortal
consist
higher
among
report
case
contrast
emerg
human
infect
sarscov
pathogen
previous
document
treatment
hpai
viru
influenza
viru
antivir
medic
document
vitro
activ
clinic
benefit
relat
suscept
season
influenza
subtyp
virus
exist
year
howev
publish
clinic
studi
antivir
treatment
human
infect
season
influenza
virus
conduct
among
otherwis
healthi
outpati
uncompl
influenza
earli
treatment
less
hour
ill
onset
assess
two
publish
retrospect
studi
treatment
among
hospit
elderli
absenc
control
clinic
treatment
trial
data
patient
hpai
viru
infect
best
guidanc
base
upon
avail
data
valid
extrapol
data
earli
treatment
season
influenza
viru
infect
larg
uncompl
influenza
among
outpati
hospit
patient
sever
hpai
diseas
especi
pathogenesi
may
differ
conven
panel
assess
avail
evid
issu
guidanc
antivir
treatment
chemoprophylaxi
viru
infect
limit
data
suggest
higher
patient
surviv
earlier
oseltamivir
treatment
standard
dose
five
day
compar
late
treatment
also
issu
guidanc
recommend
consider
higher
oseltamivir
dose
longer
durat
treatment
especi
patient
late
clinic
present
sever
diseas
recommend
routin
corticosteroid
treatment
date
clinic
data
antivir
treatment
guid
clinician
limit
multipl
challeng
confront
clinician
care
patient
suspect
confirm
viru
infect
first
hpai
viru
dynam
move
target
viru
strain
continu
evolv
multipl
genotyp
antigen
distinct
clade
subclad
least
ten
clade
viru
strain
identifi
date
viru
strain
four
clade
includ
three
subclad
clade
virus
infect
human
date
furthermor
strain
differ
vitro
antivir
suscept
profil
resist
adamantan
antivir
amantadin
rimantadin
widespread
among
clade
clade
virus
decreas
suscept
oseltamivir
identifi
viral
isol
patient
clade
clade
antivir
treatment
initi
suggest
strain
circul
among
poultri
reduc
oseltamivir
suscept
unknown
whether
higher
dose
clinic
effect
viru
strain
exhibit
reduc
vitro
oseltamivir
suscept
develop
resist
viru
oseltamivir
treatment
shown
clade
viru
strain
includ
earli
treatment
report
patient
receiv
oseltamivir
chemoprophylaxi
human
data
combin
antivir
treatment
limit
anim
data
support
benefit
combin
antivir
treatment
monotherapi
viru
infect
inde
recommend
consider
combin
antivir
treatment
adamantan
plu
neuraminidas
inhibitor
patient
infect
suscept
viru
strain
biggest
challeng
physician
initi
antivir
treatment
identifi
virusinfect
patient
earli
sever
diseas
progress
occur
nonspecif
sign
symptom
hinder
clinic
recognit
earli
diseas
patient
patient
alway
identifi
exposur
viru
fortun
viru
infect
remain
rare
worldwid
way
detect
earli
infect
test
huge
number
suspect
case
earli
viru
infect
addit
wide
avail
accur
simpl
inexpens
rapid
point
care
test
exist
current
well
antivir
medic
would
need
health
care
facil
countri
poultri
outbreak
howev
viru
may
alway
detect
upper
respiratori
tract
specimen
infect
patient
earli
ill
current
virusinfect
patient
identifi
hospit
four
six
day
ill
onset
sever
diseas
given
pathogenesi
appear
includ
high
viral
replic
lower
respiratori
tract
drive
cytokin
dysregul
therapi
besid
late
antivir
treatment
higher
dose
may
need
patient
diarrhea
may
requir
higher
dose
antivir
document
viral
dissemin
viremia
cerebrospin
fluid
brain
intestin
tract
fatal
case
suggest
intraven
treatment
may
need
highdos
oseltamivir
administr
via
oral
gastric
tube
shown
achiev
high
plasma
level
two
ventil
patient
small
number
sever
ill
patient
antivir
immunotherapi
administ
sourc
immunotherapi
convalesc
plasma
patient
surviv
particip
vaccin
clinic
trial
three
sever
ill
immunotherapi
recipi
recov
fulli
result
compel
immunotherapi
uncontrol
patient
treat
therapi
includ
antivir
administ
clearli
addit
research
therapi
need
initi
result
rais
question
whether
even
sever
ill
patient
antivir
treatment
administr
neutral
antibodi
decreas
viral
load
rapidli
dampen
cytokin
dysregul
allow
pulmonari
recoveri
clinic
care
patient
entail
much
antivir
treatment
manag
complic
acut
respiratori
distress
syndrom
hypoxemia
pleural
effus
pneumothorac
dissemin
intravascular
coagul
renal
dysfunct
multiorgan
diseas
requir
excel
intens
care
possibl
improv
standard
optim
intens
care
unit
icu
care
patient
includ
ensur
adequ
oxygen
deliveri
optim
ventil
manag
might
result
lower
mortalityeven
among
patient
admit
sever
diseas
collect
comprehens
clinic
data
detail
patient
care
train
standard
icu
care
ventil
manag
patient
clinician
countri
might
lead
improv
clinic
manag
higher
patient
surviv
infect
control
must
emphas
among
health
care
worker
famili
caregiv
set
diseas
high
mortal
avail
control
human
clinic
data
guid
clinician
patient
present
sever
diseas
number
combin
strategi
consid
therapi
patient
includ
pharmacolog
strategi
combin
antivir
treatment
antiinflammatori
agent
immunotherapi
nonpharmacolog
strategi
standard
optim
ventil
fluid
manag
especi
acut
respiratori
distress
syndrom
manag
complic
collect
detail
clinic
data
need
inform
optim
manag
patient
defin
clinic
virolog
outcom
similar
issu
confront
clinician
treat
patient
hospit
sever
lower
respiratori
tract
diseas
due
novel
swineorigin
influenza
viru
infect
current
resist
adamantan
antivir
icmj
criteria
authorship
read
met
njw
rgw
eag
tmu
contribut
write
paper
njw
rgw
eag
tmu
